Abstract
Protein folding in the cell is a complex process with a fine balance between productive and non-productive folding. To modulate, either up-regulating or down-regulating, the level of one specific protein with multiple approaches is possible, including the modulation of catalysed protein folding, the use of chemical and pharmacological chaperones, alteration of natural protein-protein interactions, the regulation of degradative pathways and manipulation of natural control mechanisms, such as the heat shock response and the unfolded protein response. Errors in proteostasis are linked to a wide range of disease states and many examples exist of the successful manipulation of proteostasis for the partial or complete elimination of the disease phenotype, including for many amyloid based diseases such as Parkinsons and Alzheimers as as well as for loss-of-function diseases such as Fabrys and Gauchers diseases. This review takes an overview of the different approaches that can be used to alter proteostasis with an emphasis on peptidomimetic inhibitors and activators of protein folding. It covers the modulators available, their mechanisms of action and potential limitations, including the problems of specificity in altering proteostasis.
Keywords: Proteostasis, protein folding, peptidomimetic, pharmacological chaperone, chemical chaperone, molecular chaperone, degradation
Current Pharmaceutical Design
Title: Modulating Proteostasis: Peptidomimetic Inhibitors and Activators of Protein Folding
Volume: 15 Issue: 21
Author(s): Feras Hatahet and Lloyd W. Ruddock
Affiliation:
Keywords: Proteostasis, protein folding, peptidomimetic, pharmacological chaperone, chemical chaperone, molecular chaperone, degradation
Abstract: Protein folding in the cell is a complex process with a fine balance between productive and non-productive folding. To modulate, either up-regulating or down-regulating, the level of one specific protein with multiple approaches is possible, including the modulation of catalysed protein folding, the use of chemical and pharmacological chaperones, alteration of natural protein-protein interactions, the regulation of degradative pathways and manipulation of natural control mechanisms, such as the heat shock response and the unfolded protein response. Errors in proteostasis are linked to a wide range of disease states and many examples exist of the successful manipulation of proteostasis for the partial or complete elimination of the disease phenotype, including for many amyloid based diseases such as Parkinsons and Alzheimers as as well as for loss-of-function diseases such as Fabrys and Gauchers diseases. This review takes an overview of the different approaches that can be used to alter proteostasis with an emphasis on peptidomimetic inhibitors and activators of protein folding. It covers the modulators available, their mechanisms of action and potential limitations, including the problems of specificity in altering proteostasis.
Export Options
About this article
Cite this article as:
Hatahet Feras and Ruddock W. Lloyd, Modulating Proteostasis: Peptidomimetic Inhibitors and Activators of Protein Folding, Current Pharmaceutical Design 2009; 15 (21) . https://dx.doi.org/10.2174/138161209788682343
DOI https://dx.doi.org/10.2174/138161209788682343 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
PLGA Nanoparticles for Nose to Brain Delivery of Clonazepam: Formulation, Optimization by 32 Factorial Design, In Vitro and In Vivo Evaluation
Current Drug Delivery Chiral Resolution and Content Determination of Ketorolac Tromethamine using High-performance Liquid Chromatography
Current Pharmaceutical Analysis Neurodegenerative Disorders Treatment: The MicroRNA Role
Current Gene Therapy Autophagy: For Better or for Worse, in Good Times or in Bad Times …
Current Molecular Medicine Elucidation of Glutamate Transporter Functions Using Selective Inhibitors
Central Nervous System Agents in Medicinal Chemistry Tyrosine Kinases as Targets for Anti-Inflammatory Therapy
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Editorial [Hot Topic:Gamma-Secretase Inhibitors and Modulators as a Therapeutic Approach to Alzheimers disease (Guest Editor: Bruno P. Imbimbo)]
Current Topics in Medicinal Chemistry Effects of Hyperlipidemia and Cardiovascular Diseases on Proliferation, Differentiation and Homing of Mesenchymal Stem Cells
Current Stem Cell Research & Therapy Maternal Nutrient Restriction is not Equivalent to Maternal Biological Stress
Current Drug Targets Therapeutic Monoclonal Antibodies and Multiple Sclerosis: The Essentials
Medicinal Chemistry Diffusion Tensor Imaging in Alzheimers Disease
Current Medical Imaging The Fate of Nanocarriers As Nanomedicines In Vivo: Important Considerations and Biological Barriers to Overcome
Current Medicinal Chemistry HIV-1, HCV and Alcohol in the CNS: Potential Interactions and Effects on Neuroinflammation
Current HIV Research Editorial [Hot Topic: Perspectives in Psychopharmacological Neuroimaging (Executive Editor: Paolo Fusar-Poli)]
Current Pharmaceutical Design Depression, Antidepressants and Hypertensive Disorders of Pregnancy: A Systematic Review
Current Drug Safety Pharmacology, Systematic Review and Recent Clinical Trials of Metadoxine
Reviews on Recent Clinical Trials Target Based Drug Design - A Reality in Virtual Sphere
Current Medicinal Chemistry Dual-acting of Hybrid Compounds - A New Dawn in the Discovery of Multi-target Drugs: Lead Generation Approaches
Current Topics in Medicinal Chemistry Role of Neural Stem Cells in Parkinsons Disease
Current Signal Transduction Therapy Neurologic Sequelae in Critical Illness: Evaluation and Outcomes
Current Respiratory Medicine Reviews